

pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group:

Lymphoma Foundation Canada

Name of drug and indication under review:

Bendamustine for 1st line treatment of NHL,
Bendamustine for NHL refractory or relapse to
rituximab-containing therapy

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. Patient advocacy groups must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the patient advocacy group input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Has this patient advocacy group received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?

Yes

No

If no, please go to Section B

2. What form of payment did this patient advocacy group receive? (Check all that apply.)

Operating Funds

Royalties

Gifts

Honoraria

Program Funding (e.g., website)

Research/educational grants

Sponsorship of Events

Other, please specify: _____

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

2012 year to date: Roche: \$ [REDACTED], Lundbeck: \$ [REDACTED], Celgene: Sanofi/Genzyme; Amgen: \$ [REDACTED], Janssen Inc: [REDACTED] 2011: Roche: \$ [REDACTED], Lundbeck: \$ [REDACTED], Celgene: \$ [REDACTED], Sanofi/Genzyme; \$ [REDACTED], Amgen: \$ [REDACTED], Janssen Inc: \$ [REDACTED]
LFC is a signatory to the CCAN Code of Conduct Governing Corporate Funding LFC has also applied and been accepted to the matched funding CIHR Shopp funding for research \$ [REDACTED] x 3 years LFC has received donations from corporate donors and in 2012 will raise over \$ [REDACTED] as a result of a tribute dinner LFC in 2011 received a Trillium grant for \$ [REDACTED]

Section B: Holdings or Other Interests

Has this patient advocacy group received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No member of the LFC Board of Directors is in possession of such stocks or options for organizations that may have a direct or indirect interest in the drug under review. As an organization, LFC owns no stocks or options.

Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

No member of the LFC Board of Directors has personal or commercial relationships of the nature stated above.
--

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Date: April 12th 2012 Name: Sue Robson

Signature: 